SCHEMBL771594

SCHEMBL771594

O=C(Cl)N1CCC2CCCC=C2C1

nearest known ligand 0.32

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.32
RAB9A P51151 3/20 0.32
ATM Q13315 1/20 0.32
L3MBTL3 Q96JM7 5/20 0.32
MBTD1 Q05BQ5 4/20 0.32
L3MBTL1 Q9Y468 3/20 0.32
TP53BP1 Q12888 1/20 0.32
L3MBTL4 Q8NA19 1/20 0.32
HSD11B1 P28845 1/20 0.32
TP53 P04637 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
ALDH1A1 P00352 1/20 0.31
POLB P06746 1/20 0.31
LMNA P02545 1/20 0.30
MAPT P10636 1/20 0.30
NFKB1 P19838 1/20 0.30
NFKB2 Q00653 1/20 0.30
RELA Q04206 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15378283 0.87 KCNH2 (0.34) NPC1RAB9AATML3MBTL3MBTD1
SCHEMBL772492 0.87 L3MBTL3 (0.33) NPC1RAB9AATML3MBTL3MBTD1
SCHEMBL2824310 0.85 RAB9A (0.35) NPC1RAB9AATML3MBTL3MBTD1
SCHEMBL2938032 0.85 RAB9A (0.35) NPC1RAB9AATML3MBTL3MBTD1
SCHEMBL770413 0.84 RBP4 (0.38) NPC1RAB9AATML3MBTL3MBTD1
SCHEMBL771592 0.83 ALDH1A1 (0.42) NPC1RAB9ASMN1; SMN2ALDH1A1POLB
SCHEMBL771656 0.83 MAPK1 (0.36) NPC1SMN1; SMN2ALDH1A1POLBLMNA
SCHEMBL770905 0.81 ALDH1A1 (0.36) L3MBTL3MBTD1L3MBTL1TP53BP1L3MBTL4
SCHEMBL7425101 0.80 PDE4B (0.43) L3MBTL1HSD11B1ALDH1A1MAPT
SCHEMBL771618 0.80 CPN1 (0.35) SMN1; SMN2ALDH1A1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 NPC1 97/4885RAB9A 2187/4885ATM 3373/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 NPC1 104/4885RAB9A 2217/4885ATM 3394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.